Novartis Ag Adr (NVS)

Dec 10, 2025

Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz

Dec 10, 2025

Dec 09, 2025

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Benzinga

Dec 09, 2025

Dec 09, 2025

Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz

Dec 09, 2025

Dec 08, 2025

DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Dec 08, 2025

Dec 07, 2025

Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.

Dec 07, 2025

Dec 05, 2025

Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView

Dec 05, 2025

Nov 29, 2025

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz

Nov 29, 2025

Nov 26, 2025

Why Novartis Stock Topped the Market Today - sharewise.com

Nov 26, 2025

Nov 25, 2025

Novartis AG Common Stock (NYSE:NVS) Stock Quote - Markets Financial Content

Nov 25, 2025

Nov 21, 2025

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz

Nov 21, 2025

Nov 20, 2025

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm

Nov 20, 2025

Nov 19, 2025

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz

Nov 19, 2025

Nov 17, 2025

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm

Nov 17, 2025

Nov 15, 2025

Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView

Nov 15, 2025

Nov 13, 2025

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz

Nov 13, 2025

Nov 06, 2025

Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail

Nov 06, 2025

Nov 05, 2025

Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily

Nov 05, 2025

Oct 29, 2025

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

Oct 29, 2025

Oct 29, 2025

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials - Novartis

Oct 29, 2025

Oct 29, 2025

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India

Oct 29, 2025

Oct 28, 2025

Novartis completes acquisition of Tourmaline Bio - Novartis

Oct 28, 2025

Oct 28, 2025

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm

Oct 28, 2025

Oct 28, 2025

Novartis announces expiration of Tourmaline Bio tender offer - Novartis

Oct 28, 2025

Oct 27, 2025

Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com

Oct 27, 2025

Oct 27, 2025

Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm

Oct 27, 2025

Oct 27, 2025

Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news

Oct 27, 2025

Oct 27, 2025

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Oct 27, 2025

Oct 27, 2025

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm

Oct 27, 2025

Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 27, 2025

Oct 26, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis

Oct 26, 2025

Oct 24, 2025

Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm

Oct 24, 2025